Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Directed differentiation and characterization of genetyically modified embryonic stem cells for therapy|
|Citation:||Methods in Molecular Biology, 2006; 329:471-484|
|Adeline A. Lau, Kim M. Hemsley, Adrian Meedeniya, Aaron J. Robinson and John J. Hopwood|
|Abstract:||Lysosomal storage disorders are rare, inherited diseases caused by a deficiency of a specific, lysosomal enzyme. In the case of mucopolysaccharidosis type IIIA, a lack of active sulfamidase enzyme results in heparan sulfate accumulation, severe and progressive neurological deficits, and usually premature death. Embryonic stem cells can be genetically modified to overexpress lysosomal enzymes, providing a renewable reservoir of cells that can be readily expanded in culture. Screening clonal lines of embryonic stem cells for desirable properties such as high levels and maintenance of enzyme activity throughout terminal differentiation to neural phenotypes theoretically provides a reproducible population of cells that can be fully characterized in vitro before implantation within the central nervous system in animal models of lysosomal storage disorders.|
|Keywords:||Clonal; differentiation; embryonic stem cells; in vitro; lysosomal enzyme; lysosomal storage; therapy; transgenic|
|Rights:||© Humana Press Inc., Totowa, NJ|
|Appears in Collections:||Paediatrics publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.